ML033430400

Emergency Plan Implementing Procedures

ML033430400
Person / Time
Site:	Catawba
Issue date:	12/01/2003
From:	Jamil D Duke Power Co
To:	Document Control Desk, Office of Nuclear Reactor Regulation
References
Download: ML033430400 (17)

Text

_ ; IPe\

ADuke D.M. JAMIL IdwPowera, Vice President A Duke Energy Company Duke Power Catawba Nuclear Station 4800 Concord Rd. / CNOIVP York, SC 29745-9635 803 831 4251 December 1, 2003 803 831 3221 fax U.S. Nuclear Regulatory Commission Attention: Document Control Desk Washington, DC 20555-0001

Subject:

Duke Energy Corporation Catawba Nuclear Station Units 1 and 2 Docket Nos. 50-413 and 50-414 Emergency Plan Implementing Procedures Please find enclosed for NRC Staff use and review the following Emergency Plan Implementing Procedure:

SH/0/B/2005/003 Distribution of Potassium Iodide Tablets in the Event of a Radioiodine Release (Rev. 000)

SH/0/B/2005/003 replaces the former site procedure, HP/0/B/1009/016, of the same title. The new procedure is a revision of the former procedure that can be used at any of Duke Power's three nuclear sites.

This revision is being submitted in accordance with 10CFR 50.54(q) and does not decrease the effectiveness of the Emergency Plan Implementing Procedures or the Emergency Plan.

There are no new regulatory commitments in this document.

By copy of this letter, two copies of the above document are being provided to the NRC, Region II.

If there are any questions, please call Tom Beadle at 803-831-4027.

Very truly D. M. Jamil Attachments 40oC S www. duke-energy. corn

U.S. Nuclear Regulatory Commission December 1, 2003 Page 2 xc (w/attachments):

L. A. Reyes U.S. Nuclear Regulatory Commission Regional Administrator, Region II Atlanta Federal Center 61 Forsyth St., SW, Suite 23T85 Atlanta, GA 30303 (w/o attachments):

R. E. Martin NRR Senior Project Manager U.S. Nuclear Regulatory Commission Mail Stop 0-8 G9 Washington, DC 20555-0001 E. F. Guthrie Senior Resident Inspector (CNS)

U.S. Nuclear Regulatory Commission Catawba Nuclear Site

I 0.

Page I of 4 DUKE POWER COMPANY CATAWBA NUCLEAR STATION EMERGENCY PLAN IMPLEMENTING PROCEDURES INDEX VOLUME I PROCEDURE TITLE RP/0/A/5000/O0 1 Classification of Emergency (Rev. 015)

RP/O/A/5000/002 Notification of Unusual Event (Rev. 036)

RP/O/A/5000/003 Alert (Rev. 039)

RP10/A/5000/004 Site Area Emergency (Rev. 041)

RPIO/A/50001005 General Emergency (Rev. 041)

RPIO/A/5000/06 Deleted RP/01A/50001006 A Notifications to States and Counties from the Control Room (Rev. 016)

RP/O/A/50001006 B Notifications to States and Counties from the Technical Support Center (Rev. 016)

RP/0/A/50001006 C Deleted RP/01A/5000/007 Natural Disaster and Earthquake (Rev. 021)

RPIO/A/5000/08 Deleted RP/0/B1/5000/008 Spill Response (Rev. 021)

RPlO/A/5000/009 Collision/Explosion (Rev. 007)

RP/01A1500010 10 Conducting A Site Assembly or Preparing the Site for an Evacuation (Rev. 016)

RP/O/A/5000/1 1 Deleted RP/OIB15000/12 Deleted RP/01B15000/013 NRC Notification Requirements (Rev. 029)

RPI0/B/5000/14 Deleted RPIO/A/5000/0 15 Core Damage Assessment (Rev. 005)

RP/OIB/500010 16 Deleted RPI0IBI5000/ 17 Deleted December 1, 2003

f -

Page 2 of 4 DUKE POWER COMPANY CATAWBA NUCLEAR STATION EMERGENCY PLAN IMPLEMENTING PROCEDURES INDEX VOLUME I PROCEDURE TITLE RP/0/A/5000/018 Emergency Worker Dose Extension (Rev. 001)

RP/0/B1/5000/019 Deleted RP/O/A/5000/020 Technical Support Center (TSC) Activation Procedure (Rev. 018)

RP/O/A/50001021 Deleted RP/0/13/5000/022 Evacuation Coordinator Procedure (Rev. 004)

RP/0/13/5000/023 Deleted RPIO/A/5000/024 OSC Activation Procedure (Rev. 012)

RP0/3B/5000/025 Recovery and Reentry Procedure (Rev. 003)

RPI0/B1/5000/026 Site Response to Security Events (Rev. 005)

K.) RP/0/B15000/028 Communications and Community Relations EnergyQuest Emergency Response Plan (Rev. 001)

December 1, 2003

I-Page 3 of 4 DUKE POWER COMPANY CATAWBA NUCLEAR STATION EMERGENCY PLAN IMPLEMENTING PROCEDURES INDEX VOLUME 11 PROCEDURE TITLE HP10/B/1000/006 Emergency Equipment Functional Check and Inventory (Rev. 055)

HP/0/B/31009/001 Radiation Protection Recovery Plan (Rev. 008)

HP/0/1B/ 1009/003 Radiation Protection Response Following a Primary to Secondary Leak (Rev. 008)

HP/O/B/1009/004 Environmental Monitoring for Emergency Conditions Within the Ten-Mile Radius of CNS (Rev. 028)

HP/0/B/1009/005 Personnel/Vehicle Monitoring for Emergency Conditions (Rev. 016)

HPIO/B/1009/006 Alternative Method for Determining Dose Rate Within the Reactor Building (Rev. 008)

HP/0/B/ 1009/007 In-Plant Particulate and Iodine Monitoring Under Accident Conditions (Rev. 019)

HP/O/B/10091008 Contamination Control of Injured Individuals (Rev. 015)

HP/0/B/1009/009 Guidelines for Accident and Emergency Response (Rev. 039)

HP/O/B/1009/014 Radiation Protection Actions Following an Uncontrolled Release of Radioactive Material (Rev. 008)

HPIO/B/1009/016 Deleted HP/0/3/ 1009/017 Deleted HP/l/B/1009/017 Deleted HP/2/1B/1009/017 Deleted HP/0/B/ 1009/018 Deleted HP1O/B/1009/019 Emergency Radio System Operation, Maintenance and Communication (Rev. 010)

HPIO/B/1009/024 Implementing Procedure for Estimating Food Chain Doses Under Post-Accident Conditions (Rev. 002)

December 1, 2003

Page 4 of 4 DUKE POWER COMPANY CATAWBA NUCLEAR STATION EMERGENCY PLAN IMPLEMENTING PROCEDURES INDEX VOLUME 11 PROCEDURE TITLE HP/0IB/1009/025 Deleted HP/O/B/ 1009/026 On-Shift Offsite Dose Projections (Rev. 005)

SH/0/B1/20051001 Emergency Response Offsite Dose Projections (Rev. 002) (Restricted Change)

SH/01B/2005/002 Protocol for the Field Monitoring Coordinator During Emergency Conditions (Rev. 002)

SH/0/13/2005/003 Distribution of Potassium Iodide Tablets in the Event of a Radioiodine Release (Rev. 000)

OP/O/A16200/021 Deleted SRIOB/2000/001 Standard Procedure for Public Affairs Response to the Emergency Operations Facility (Rev. 004)

SR/0/B1/2000/002 Standard Procedure for EOF Services (Rev. 003)

SR/0/B/2000/003 Activation of the Emergency Operations Facility (Rev. 010)

SR/O/B/2000/004 Notification to States and Counties from the Emergency Operations Facility (Rev. 006)

December 1, 2003

November 19, 2003 To: CNS EPIP Manual Holders:

Please delete the following procedure from your Catawba Nuclear Station Emergency Plan Implementing Procedures Manual:

HP/0/B/1009/016, Distribution of Potassium Iodide Tablets in the Event of a Radioiodine Release This site procedure is being replaced by a new shared procedure (SIO/B/2005/003) of the same title which can be used at any of Duke Power's three nuclear sites.

E. T. Beadle Emergency Planning Manager

(R04-01) Duke Power Company (1) ID No. SI/01/J/2005/003 PROCEDURE PROCESS RECORD Revision No. 000 FOR STANDARD PROCEDURES PREPARATION (2) Procedure

Title:

_ . Distribution of Potassium Iodide Tablets' in the Event of a Radioiodine Release (3) Prepared By_ Aaalm Date / ?-Ds8 (4) Applicable To: I ONS MNS CNS (5) Technical i -~-~z / A .

Advisor L lj/r I1/0I03AA3e [ 3 (6) Requires ' Yes 0 No l1 Yes 0 No IN Yes 0 V NSD 228 , .

Applicability . YES = New procedure.or reissue.with-major.changes Determination NO = Reissue with minor changes OR to incorporate previously approved changes (7) Review (QR) By -'/ goj By By B

Date 2/0/azLo . Date 10/l/ 9. Date VZ' 21/ 3 Cross-Disciplinary By Bytao1, /XA- By e4 j2 Review (QR) NA Date NA Date (o/6/Q5 NA Date Review (OR)

Invlvmet Reactivt NA By, Date i /o/.Z ' NA By.

Date c7..

NA4/ Date______

y____________

Review(Ops Supt)

D (8) Additional By (QABy y (QA) By (QA)

Reviews Date Date Date By L y4 By__________

DateA0l 1!-.. te/Date_______________

(9) Approved By .r -i%'e.-- 13 Date U'!l?4h<~1 DateI/'ZS -&3 Date Z--6 93 (10) Use Level Reference Usc PERFORMANCE (Compare with Control Copy every 14 calendar days while work is being performed.)

(11) Compared with Control Copy Date Compared with Control Copy Date Compared with Control Copy_ Date (12) Date(s) Performed Work Order Number (WO#)

COMPLETION (13) Procedure Completion Verification o Yes 0 NA Check lists or blanks properly initialed, signed, dated, or filled in NA, as appropriate?

O Yes 0 NA Required enclosures attached?

O Yes 0 NA Data sheets attached, completed, dated, and signed?

O Yes 0 NA Charts, graphs. etc., attached and properly dated, identified, and marked?

o Yes 0 NA Procedure requirements met?

Verified By Date (14) Procedure Completion Approved Date (15) Remarks (attach additional pages, if necessary)

Duke Power Company Procedure No.

Standard Procedure for Oconee, McGuire, and Catawba SIVO/B/2005/003 Nuclear Stations Revision No.

Distribution of Potassium Iodide Tablets 000 in the Event of a Radioiodine Release Electronic Reference No.

Reference Use SHROOOG

SIuIO/B/2005/003 Page 2 of 5 Distribution of Potassium Iodide Tablets in the Event of a Radioiodine Release

1. Purpose 1.1 This procedure provides information necessary to distribute Active Potassium Iodide (KI) tablets to Emergency Response Organization (ERO) personnel in the event of a release of radioiodine resulting from emergency conditions.

1.2 This procedure also outlines storage and supply information to assure sufficient quality and quantity of thyroid blocking materials -- - - __-___

1.3 The level of use for this procedure is "Reference Use".

1.4 This procedure is an Emergency Plan Implementing Procedure (EPIP) for MNS, CNS, and ONS. This procedure must be forwarded to the Emergency Planning Group at each site within 3 working days of approval by the responsible group (PIP 0-93-0701).

2. References 2.1 NCRP Report No. 55; Protection of the Thyroid Gland in the Event of Releases of Radioiodine 1977 2.2 NCRP Report No. 65; Management of Persons Accidentally Contaminated with Radionuclides 1980 2.3 BRH Report; Recommendations of Thyroid Blocking EKI, HHS Pub. FDA 81-8158 2.4 Radiation Protection Standard Procedure SIJ101B/2001/001, Internal Dose Assessment 2.5 Radiation Protection Policy Manual VI-05, Radiation Accident and Emergency Procedures 2.6 PIP 0-93-701, Distribution of Emergency Plan Procedures 2.7 EPA 400-R-92-001, Manual of Protective Action Guides And Protective Actions For Nuclear Incidents 2.8 Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies, FDA Guidance, November, 2001 2.9 Guidance for Industry, KI in Radiation Emergencies, Questions and Answers, FDA, December, 2002 2.10 Title 10, Code of Federal Regulations, Part 20 (10CFR20)

SWOI/B/2005/003 Page 3 of 5

3. Limits and Precautions WARNING: Persons who are known to be allergic to KI, iodine, or with pre-existing thyroid disease (e.g., Graves disease, thyroid nodules, Hashimoto's Thyroiditis) shall NOT receive these tablets.

~~~ ~

a~ ~ ~ ~ ~ ~~~~~~~_

WARNING: Nursing mothers who receive KI tablets shall be advised to use nutrient substitutes I - - (e;g., milk or a formula) for children for the duration of the ten-day tablet-use-period.

NOTE: Best results shall be achieved when KI tablets are administered prior to an exposure or immediately after an exposure (within 2 hours2.314815e-5 days <br />5.555556e-4 hours <br />3.306878e-6 weeks <br />7.61e-7 months <br />). Administration as late as 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br /> after the exposure is of less value but still significant enough to justify the administering.

4. Procedure 4.1 Registration of Personnel 4.1.1 The Radiation Protection Manager shall evaluate the distribution of KI for personnel who meet any of the following conditions:

• Personnel suspected of being in an affected area prior to the detection of a radioiodine release

• Personnel known to have been in an affected area

• Personnel who have a need to enter an affected area 4.1.2 Use Enclosure 5.3 to document the actual orexpected DAC-hrs of exposure.

NOTE: K1 shall be distributed only to prevent a "significant uptake" of radioiodine. A significant uptake is defined as follows:

• That amount of radioiodine taken into the body that wvould result in a Committed Dose Equivalent (CDE) of 5 rem or more to the thyroid. (Reference 2.8 and 2.9)

X 5 rem CDE to the thyroid is equal to 200 DAC-hrs of iodine exposure. (Reference 2.10) 4.1.3 IF the actual or expected DAC-hrs of exposure is equal to or exceeds 200 DAC-hrs, recommend that the personnel take KI.

SIuIO/B/20051003 Page 4 of 5 4.1.4 IF determination is made to distribute KI tablets for ingestion by ERO personnel, notify the Emergency Coordinator AND EOF Director of decision.

4.1.5 Complete Enclosure 5.1 for personnel that are to be given KI.

4.1.6 Retain completed procedure in Master Bile.

4.2 Distribution of Potassium Iodide NOTE: It is NOT mandatory for any person to take or ingest KI tablets.

4.2.1 Discard any KI bottles that have loose tops.

4.2.2 Discard any KI bottles that are past their expiration date.

4.2.3 Discard any tablets that are disfigured or discolored.

4.2A Advise personnel NOT to deviate from the prescribed dosages and dosage rates.

4.2.5 Explain that the prescribed dose is one (1) tablet per day for 10 consecutive days.

4.2.6 Explain that the bottle of KI that the personnel shall be given contains fourteen (14) tablets. The four (4) unused tablets shall be discarded.

4.2.7 Explain that tablets should be taken as close to a 24-hour time period as possible.

4.2.8 Issue one (1) bottle containing fourteen (14) KI tablets to each affected personnel.

4.2.9 Instruct the personnel to ingest the tablet.

4.2.10 Give one (1) package insert to each affected personnel.

4.2.11 Return all unopened KI tablets to the emergency kit.

SHiO/B/2005/003 Page 5 of 5 4.3 Internal Dose Assessment Following Radioiodinc Exposure NOTE: The maximum iodine concentration in the thyroid is expected to occur approximately 12 hours1.388889e-4 days <br />0.00333 hours <br />1.984127e-5 weeks <br />4.566e-6 months <br /> post-exposure (Reference 2.2).

4.3.1 Schedule all employees receiving KI tablets for a body burden analysis (BBA) approximately 12 hours1.388889e-4 days <br />0.00333 hours <br />1.984127e-5 weeks <br />4.566e-6 months <br /> after the suspected or actual exposure.

4.3.2 Assess the internal dose per Reference 2.4.

4.4 Storage and Supply Requirements for ICI Tablets 4.4.1 Replacement KI tablets shall be ordered at least 3 months prior to date of expiration of the current-stock KI tablets.

4.4.2 Upon receiving a shipment of KI, the boxes shall be opened and examined as soon as possible.

4.4.3 Discard any bottles in which the air-tight seal has been broken.

4.4.4 Discard the old KI tablets.

4.4.5 Store the KI tablets in the following manner.

4.4.5.1 Store in an area protected from exposure to light.

4.4.5.2 Store in an area of low humidity.

4.4.5.3 Store in an area where the temperature range is 68 to 77 degrees F.

5. Enclosures 5.1 Potassium Iodide Tablet Distribution Data Sheet 5.2 Package Insert for Thyro-Blocktm Tablets 5.3 DAC-Hour Determination

(s EnclosureC SWO/B/2005/003 ( .)

Potassium Iodide Tablet Distribution Page l of I Data Sheet I have been provided written Instruction for the use of Potassium Iodide (KI) tablets. I have read these instructions and Intend to use KI in accordance with the manufacturer's instructions. My signature below indicates that I acknowledge that any additional guidance for KI use shall be obtained from a medical authority or the Radiation Protection Manager or designee.

RP Badge Printed Date/Time of Date & Time of Number Name Signature Department. Suspected or Initial KI Date/Time Projected Exposure Issuance

--~~:

RP Signature: I Date/Time:I

I Enclosure 5.2 SIO/(B/2005/003 Package Insert for Tliyro-BlockThi Tablets Page 1 of 2 Patent Package Insert For THYRO-BLOCKTh (POTASSIUM IODIDE)

(pronounced poe-TASS-e-um EYE-oh-dyed)

(abbreviated: KI)

TABLETS U.S.P.

IN A RADIATION EMERGENCY, -RADIOACTIVE IODINE COULD BE RELEASED INTO THE AIR.

POTASSIUM IODIDE (A FORM OF IODINE) CAN HELP PROTECT YOU.

IF YOU ARE TOLD TO TAKE THIS MEDICINE. TAKE IT ONE TIME EVERY 24 HOURS. DO NOT TAKE IT MORE OFTEN. MORE WILL NOT HELP YOU AND MAY INCREASE THE RISK OF SIDE EFFECTS. DO NOT TAKE THIS DRUG IF YOU KNOW YOU AREALLERGIC TO IODIDE. (SEE SIDE EFFECTS BELOW.)

, INDICATIONS THYROID BLOCKING IN A RADIATION EMERGENCY ONLY DIRECTIONS FOR USE Use only as directed by State or local public health authorities in the event of a radiation emergency.

DOSE Tablets: ADULTS AND CHILDREN I YEAR OF AGE OR OLDER: One (1) tablet once a day.

Crush for small children.

BABIES UNDER I YEAR OF AGE: One-half (1/2) tablet once a day. Crush first.

Take for 10 days unless directed otherwise by State or local public health authorities.

Store at controlled room temperature between 200 and 25 0C (68°- 77F9). Keep container tightly closed and protect from light.

WARNING Potassiumiodide should NOT be used by people allergicto iodide.

Keep out of the reach of children. In case of overdose or allergic reaction, contact a physician or the public health authority.

DESCRIPTION Each THYRO-BLOCKrm TABLET contains 130mg of potassium iodide.

Other ingredients:

Magnesium stearate, microcrystalline cellulose, silica gel, and sodium thiosulfate

Enclosure 5.2 SW0I/B/2005/003 Package Insert for Thyro-BlockT^' Tablets Page 2 of 2 HOW POTASSIUM IODIDE WORKS Certain forms of iodine help your thyroid gland work right. Most people get the iodine they need from foods, like iodized salts or fish. The thyroid can "store" or hold only a certain amount of iodine.

In a radiation emergency, radioactive iodine may be released in the air. This material may be breatheZinr swallowed. It may enter the thyroid gland and damage it. The damage would probably NOT show itself for years. Children are most likely to have thyroid damage.

IF you take potassium iodide, it will fill-up your thyroid gland. This reduces the chance that harmful radioactive iodine will enter the thyroid gland.

WHO SHOULD NOT TAKE POTASSIUM IODIDE The only people who should NOT take potassium iodide are people who know they are allergic to iodide. You may take potassium iodide even if you are taking medicines for a thyroid problem (for example, a thyroid hormone or antithyroid drug). Pregnant and nursing women and babies and children may also take this drug.

HOW AND WHEN TO TAKE POTASSIUM IODIDE Potassium Iodide should be taken as soon as possible after public health officials tell you. You should take one dose every 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br />. More will NOT help you because the thyroid can 'hold" only limited amounts of iodine. Larger doses will increase the risk of side effects. You will probably be told NOT to take the drug for more than 10 days.

SIDE EFFECTS Usually, side effects of potassium iodide happen when people take higher doses for a long time. You should be careful NOT to take more than the recommended dose or take it for longer than you are told. Side effects are unlikely because of the low dose and the short time you will taking the drug.

Possible side effects include skin rashes, swelling of the salivary glands, and "iodism" (metallic taste, burning mouth and throat, sore teeth and gums, symptoms of a head cold, and sometimes stomach upset and diarrhea).

A few people have an allergic reaction with more serious symptoms. These could be fever and joint pains, or swelling of parts of the face and body and at times severe shortness of breath requiring immediate medical attention.

Taking iodide may rarely cause overactivity of the thyroid gland, underactivity of the thyroid gland, or enlargement of the thyroid gland (goiter).

WHAT TO DO IF SIDE EBFFECTS OCCUR IF the side eff&ts are severe or if you have an allergic reaction, stop taking potassium iodide. Then, if possible, call a doctor or public health authority for instructions.

HOW SUPPLIED THYRO-BLOCK'm TABLETS (Potassium Iodide. U.S.P) are white round tablets, one side scored, other debossed 472 Wallace, each containing 130 mg potassium iodide. Available in bottles of 14 tablets (NDC 0037-0472-20).

WALLACE LABORATORIES Division of CARTER-WALLACE, INC.

Cranbury, New Jersey 08512 IN-0472 04 Rev. 5198

Enclosure 53 SI-YO/B/2005/003 DAC-Hour Determination Page 1 of 1 Nuclide Conc DAC* Expected DAC (ACUml) ttCi/ml) Exposure Hours Time lirs 1-131 2E-8 x I-133 - * . 1E-7 x I-135 *I___ 7E-7 x Total DAC-Hrs ->

LII IF total DAC-hrs is 200 or greater, the use of KI is recommended.

RP Signature:

Date/Time:

• DAC per Reference 2.10